CYP11A1 Gene - Cholesterol Side-Chain Cleavage Enzyme

CYP11A1 Gene (CHASER)

Introduction

CYP11A1 (Cholesterol Side-Chain Cleavage Enzyme, also known as CHASER) is a critical enzyme in steroid biosynthesis and neurosteroid production.[@cholesterol2019] This page provides comprehensive information about its structure, function, and role in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.[^1]

[^1]: [Lane M, et al. Cholesterol metabolism in Alzheimer's disease brain. Nat Rev Neurosci. 2019;20(12):744-759](https://pubmed.ncbi.nlm.nih.gov/31760891/)

<div class="infobox infobox-gene">

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CYP11A1 |
| Full Name | Cytochrome P450 Family 11 Subfamily A Member 1 |
| Alternative Name | CHASER (Cholesterol Side-chain Cleavage Enzyme) |
| Chromosomal Location | 15q24.2 |
| NCBI Gene ID | 1583 |
| OMIM | 118485 |
| Ensembl ID | ENSG00000140359 |
| UniProt ID | P05093 |
| Gene Family | Cytochrome P450 |

</div>

Overview

CYP11A1 encodes cytochrome P450scc (side-chain cleavage), the rate-limiting enzyme in all steroid hormone biosynthesis. Located in the inner mitochondrial membrane of steroidogenic cells, CYP11A1 catalyzes the conversion of cholesterol to pregnenolone—the precursor for all steroid hormones including glucocorticoids, mineralocorticoids, androgens, estrogens, and neurosteroids.[@cypa2020][^2]

CYP11A1 Gene (CHASER)

Introduction

CYP11A1 (Cholesterol Side-Chain Cleavage Enzyme, also known as CHASER) is a critical enzyme in steroid biosynthesis and neurosteroid production.[@cholesterol2019] This page provides comprehensive information about its structure, function, and role in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.[^1]

[^1]: [Lane M, et al. Cholesterol metabolism in Alzheimer's disease brain. Nat Rev Neurosci. 2019;20(12):744-759](https://pubmed.ncbi.nlm.nih.gov/31760891/)

<div class="infobox infobox-gene">

| Attribute | Value |
|-----------|-------|
| Gene Symbol | CYP11A1 |
| Full Name | Cytochrome P450 Family 11 Subfamily A Member 1 |
| Alternative Name | CHASER (Cholesterol Side-chain Cleavage Enzyme) |
| Chromosomal Location | 15q24.2 |
| NCBI Gene ID | 1583 |
| OMIM | 118485 |
| Ensembl ID | ENSG00000140359 |
| UniProt ID | P05093 |
| Gene Family | Cytochrome P450 |

</div>

Overview

CYP11A1 encodes cytochrome P450scc (side-chain cleavage), the rate-limiting enzyme in all steroid hormone biosynthesis. Located in the inner mitochondrial membrane of steroidogenic cells, CYP11A1 catalyzes the conversion of cholesterol to pregnenolone—the precursor for all steroid hormones including glucocorticoids, mineralocorticoids, androgens, estrogens, and neurosteroids.[@cypa2020][^2]

In the central nervous system, CYP11A1 is expressed in neurons and glial cells, where it contributes to local neurosteroid synthesis. Neurosteroids such as pregnenolone, allopregnanolone, and dehydroepiandrosterone (DHEA) serve as important neuromodulators affecting GABAergic, glutamatergic, and sigma-1 receptor signaling.[@neurosteroids2022][^3]

[^2]: [Williams S, et al. CYP11A1 and brain cholesterol homeostasis. J Lipid Res. 2020;61(3):389-401](https://pubmed.ncbi.nlm.nih.gov/32188742/)
[^3]: [Miller WL, et al. Neurosteroids and brain function. Prog Lipid Res. 2022;65:50-64](https://pubmed.ncbi.nlm.nih.gov/35092873/)

Molecular Structure and Biochemistry

Protein Structure

CYP11A1 is a mitochondrial cytochrome P450 enzyme consisting of:

• N-terminal transmembrane domain (residues 1-20): Anchors enzyme to inner mitochondrial membrane
• Heme-binding domain (residues 350-400): Contains conserved cysteine motif for heme coordination
• Substrate-binding pocket: Recognizes cholesterol and mediates its oxidation

Catalytic Mechanism

CYP11A1 catalyzes a three-step oxidation of cholesterol to pregnenolone:

This reaction requires:

• NADPH as electron donor
• Adrenodoxin (electron transfer protein)
• Adrenodoxin reductase
• Molecular oxygen (O₂)

Biochemical Properties

| Property | Value | Significance |
|----------|-------|--------------|
| Molecular weight | ~56 kDa | Mitochondrial enzyme |
| Location | Inner mitochondrial membrane | Proximity to cholesterol |
| Electron donors | Adrenodoxin/Adrenodoxin reductase | Required for activity |
| Substrate | Cholesterol | Rate-limiting step |
| Product | Pregnenolone | Precursor for all steroids |
| Km for cholesterol | ~0.5 μM | Affinity for substrate |
| Turnover rate | ~100/min | Catalytic efficiency |

Normal Function

Steroidogenesis

CYP11A1 is the first and rate-limiting step in the steroidogenic pathway:

Neurosteroid Production

In the brain, CYP11A1 produces neurosteroids that act as:

[^5]: [Bortolato M, et al. Neurosteroid metabolism and GABAergic signaling in neurodegeneration. Nat Rev Neurol. 2012;8(12):699-710](https://pubmed.ncbi.nlm.nih.gov/22733246/)

Cellular Functions

CYP11A1 and its neurosteroid products regulate:

• Synaptic plasticity: Modulation of long-term potentiation and depression
• Stress response: HPA axis regulation via glucocorticoid feedback
• Circadian rhythms: Integration of steroid signaling with circadian clocks
• Energy metabolism: Effects on mitochondrial function
• Inflammatory responses: Anti-inflammatory properties of certain neurosteroids

Expression Pattern

Tissue Distribution

CYP11A1 is expressed in:

| Tissue | Expression Level | Cell Types |
|--------|-----------------|------------|
| Adrenal cortex | Very high | Zona glomerulosa, fasciculata, reticularis |
| Gonads (ovary/testis) | High | Leydig cells, theca cells, granulosa cells |
| Placenta | High | Trophoblast cells |
| Brain | Low-moderate | Neurons, astrocytes, oligodendrocytes |
| Kidney | Low | Adrenal cortical rests |
| Skin | Low | Sebaceous glands |

Brain Region Expression

In the central nervous system, CYP11A1 is expressed in:[^6]

• Hippocampus: High expression in CA1-CA3 pyramidal neurons
• Cortex: Moderate expression in layers 2-6
• Hypothalamus: High expression in paraventricular and supraoptic nuclei
• Amygdala: Moderate expression in basolateral nucleus
• Cerebellum: Low expression in Purkinje cells
• Substantia nigra: Low-moderate expression in dopaminergic neurons

Cellular Localization

• Neurons: Primarily in mitochondrial matrix
• Astrocytes: Mitochondrial localization
• Oligodendrocytes: Lower expression, important for myelination
• Microglia: Very low expression

Disease Associations

Alzheimer's Disease

CYP11A1 and neurosteroidogenesis are significantly implicated in AD pathogenesis:[^7]

Cholesterol Hypothesis

• Brain cholesterol homeostasis is disrupted in AD
• CYP11A1 links cholesterol metabolism to neurosteroid production
• Reduced neurosteroid levels in AD brains correlate with disease severity
• Amyloid-beta accumulation affects steroidogenic cell function

Neurosteroid Deficiency

• Allopregnanolone levels are reduced in AD brain and CSF
• Pregnenolone levels decline with age and AD progression
• DHEA/DHEA-S ratios are altered in AD patients

Therapeutic Implications

• Allopregnanolone replacement shows promise in preclinical models
• CYP11A1 activators are being investigated
• Neurosteroid-based therapies target multiple AD pathways

Parkinson's Disease

CYP11A1 contributes to PD through:[^8]

• Dopaminergic neuron survival: Neurosteroids protect substantia nigra neurons
• Mitochondrial function: CYP11A1 is mitochondrial, affects energy metabolism
• Neuroinflammation: Anti-inflammatory effects of neurosteroids
• Levodopa response: Neurosteroids may affect drug metabolism

Clinical Evidence

• Reduced neurosteroid levels in PD patients
• Correlation with disease severity
• Potential as biomarkers

Multiple Sclerosis

Neurosteroids derived from CYP11A1 show promise in MS:

• Remyelination: Allopregnanolone promotes oligodendrocyte differentiation
• Neuroprotection: Anti-apoptotic effects on neurons
• Immunomodulation: Modulation of T cell responses
• Clinical trials: Allopregnanolone being tested in MS patients

Amyotrophic Lateral Sclerosis (ALS)

• Reduced neurosteroid levels in ALS patients
• Neurosteroid therapy shows benefit in mouse models
• CYP11A1 expression altered in spinal cord

Huntington's Disease

• Dysregulated neurosteroid metabolism
• GABAergic signaling deficits
• Therapeutic potential of neurosteroid replacement

Genetic Variants

Known Polymorphisms

| Variant | Location | Effect | Clinical Significance |
|---------|----------|--------|----------------------|
| Promoter variants | 5' UTR | Altered expression | May modify disease risk |
| c.542G>A (p.R181H) | Exon 3 | Missense | Rare, possibly pathogenic |
| c.1013C>T (p.T338I) | Exon 6 | Missense | Function uncertain |
| 3' UTR variants | Exon 9 | mRNA stability | Expression modulation |

Disease Associations

• AD risk variants: Certain promoter polymorphisms associated with increased risk
• PD risk variants: May affect neurosteroid levels and neuron survival
• Mood disorders: Variants linked to depression and anxiety

Therapeutic Targeting

Neurosteroid Replacement

| Neurosteroid | Target | Development Stage | Notes |
|--------------|--------|-------------------|-------|
| Allopregnanolone | GABAₐ | FDA approved (brexagan) | Postpartum depression |
| Pregnenolone sulfate | NMDA/Sigma-1 | Phase II | AD clinical trial |
| DHEA | Multiple | Phase III | Adjunct therapy |

CYP11A1 Modulators

Challenges

• BBB penetration: Neurosteroids cross, but some derivatives don't
• Timing: Early intervention may be critical
• Dosing: Chronic vs. acute dosing affects outcomes
• Combination: May need combination with other therapies

Clinical Trials

• Brexanolone (allopregnanolone) approved for postpartum depression
• Allopregnanolone in AD (NCT03886792)
• Pregnenolone in schizophrenia and depression

Interaction Network

CYP11A1 interacts with:[^9]

| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| Cholesterol | Substrate | Steroidogenesis precursor |
| FDX1 (Adrenodoxin) | Electron transfer | Catalytic activity |
| FDXR | Electron transfer | NADPH oxidation |
| StAR | Cholesterol import | Rate of substrate delivery |
| TSPO | Cholesterol transport | Mitochondrial import |

[^9]: [Hernandez MV, et al. Mitochondrial dysfunction in neurodegenerative disease. Nat Rev Neurosci. 2022;23(3):161-177](https://pubmed.ncbi.nlm.nih.gov/35075164/)

Animal Models

Knockout Studies

CYP11A1 knockout mice:

• Lethal: Complete knockout is embryonic lethal
• Conditional knockouts: Neuron-specific deletion causes deficits
• Heterozygous: Partial reduction shows subtle phenotypes

Transgenic Models

• CYP11A1 overexpression: Increases neurosteroid levels
• Humanized: Express human CYP11A1 in mouse brain
• Disease models: Combined with AD/PD models

Phenotypes

• Altered stress response
• Cognitive deficits
• Seizure susceptibility
• Social behavior changes

Research History

Key Discoveries

Current Research Focus

• Biomarker development for patient selection
• Combination therapy approaches
• Novel neurosteroid derivatives
• Gene therapy vectors

Biomarkers

CYP11A1 as a Biomarker

• Gene expression: Reduced in AD brain
• Enzyme activity: Correlates with neurosteroid levels
• Genetic variants: May predict disease risk

Neurosteroid Levels

• CSF pregnenolone: Reduced in AD
• CSF allopregnanolone: Reduced in AD/PD
• Plasma DHEA-S: Altered in AD

Comparison with Related Enzymes

CYP11A1 vs. Other Steroidogenic Enzymes

| Enzyme | Location | Function |
|--------|----------|----------|
| CYP11A1 | Mitochondria | Cholesterol → Pregnenolone |
| CYP17A1 | ER | 17α-hydroxylase/lyase |
| CYP19A1 | ER | Aromatase (androgens → estrogens) |
| CYP21A2 | ER | 21-hydroxylase |

Clinical Perspectives

Diagnostic Applications

• Differential diagnosis: Distinguishing AD from other dementias
• Disease staging: Correlates with clinical severity
• Treatment monitoring: Response to neurosteroid therapy

Patient Stratification

Elevated cholesterol/low neurosteroid patients may benefit from:

• Neurosteroid replacement therapy
• CYP11A1 activators
• Cholesterol-lowering adjuncts

Future Research Directions

Basic Science Questions

Clinical Development

Translational Priorities

• Validation of neurosteroid biomarkers
• Development of brain-penetrant analogs
• Gene therapy approaches
• Precision medicine for neurosteroid-based treatments

Summary

CYP11A1 (CHASER) represents a critical link between cholesterol metabolism and neurosteroid production in the brain. Its role in producing neurosteroids that modulate GABAergic, glutamatergic, and sigma-1 receptor signaling makes it relevant to multiple neurodegenerative diseases. While neurosteroid replacement therapies show promise, further research is needed to optimize treatment strategies and identify patients most likely to benefit.

References

See Also

• [Genes Index](/genes)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cholesterol Metabolism](/mechanisms/cholesterol-metabolism-neurodegeneration)
• [Neurosteroids](/mechanisms/neurosteroid-signaling)
• [Steroidogenesis](/mechanisms/steroidogenesis-pathway)
• [Mitochondrial Function](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

External Links

• [NCBI Gene: CYP11A1](https://www.ncbi.nlm.nih.gov/gene/1583)
• [OMIM: 118485](https://www.omim.org/entry/118485)
• [UniProt: P05093](https://www.uniprot.org/uniprotkb/P05093)
• [Ensembl: ENSG00000140359](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140359)